Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic stroke

Neurological Research

Volumn 18, Issue 1, 1996, Pages 45-48

  Bednar, Martin M ^a   Raymond Russell, Sheila J ^a   Booth, Christina L ^a   Gross, Cordell E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

antiplatelet; Rabbits; stroke; t PA; thrombolysis; ticlopidine

Indexed keywords

ANTITHROMBOCYTIC AGENT; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; DRUG EFFECT; DRUG SCREENING; FEMALE; FIBRINOLYTIC THERAPY; INTERNAL CAROTID ARTERY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RABBIT; STROKE;

EID: 0030026308     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1080/01616412.1996.11740376     Document Type: Article

References (14)

1. Third International Study of Infarct Survival Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770
2. Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke: Does it work? Stroke 1992; 23: 1826-1839
3. Gross CE, Raymond SR, Howard DB, Bednar MM. Delayed tissue plasminogen activator therapy in a rabbit model of thromboembolic stroke. Neurosurgery 1995; 36: 1172-1177
4. Akashi A, Tamura K, Hirohashi M, Watanabe K, Kasahara A. Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Arzneim- Forsch/Drug Res 1980; 30: 409-414
5. Saltiel E, Ward A. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262
6. Young W. Hydrogen clearance measurement of blood flow: A review of technique and polarographic principles. Stroke 1980, 11: 552-564
7. Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993; 24: 117-121
8. Bednar MM, Dooley RH, Zamani M, Howard DB, Gross CE. Neutrophil and platelet activity and quantification following delayed t-PA therapy in a rabbit model of thromboembolic stroke. J Thromb Thrombolysis 1995; 1: 179-185
9. Thomas GR, Thibodeux H, Errett CJ, Bednar MM, Gross CE, Bennett WR. Iloprost reverses a paradoxical aspirin-induced attenuation of cerebral clot lysis using tissue type plasminogen activator in a rabbit model of embolic stroke. Stroke, 1995; 26:1039-1046
10. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanisms of action. Stroke 1990; 221: IV.12-IV.23
11. Lagarde M, Ghazai I, Dechavanne M. Effects of ticlopidine on platelet prostaglandin metabolism: Possible consequences for prostacyclin production. Prostaglandins Med 1979; 2: 433-440
12. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts II, LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-686
13. Jones TH, Morawetz RB, Crowell RM, Marcoux FW, Fitzgibbon SJ, DeGirolami U, Ojemann RG. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54: 773-782
14. Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, Fukuyama M, Itagaki I. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994; 25: 1547-1551